Breaking News Instant updates and real-time market news.

EMNSF

Elementis

$2.00 /

+ (+0.00%)

19:49
05/18/21
05/18
19:49
05/18/21
19:49

Elementis price target raised to 170 GBp from 155 GBp at Jefferies

Jefferies analyst Jaroslaw Pominkiewicz raised the firm's price target on Elementis to 170 GBp from 155 GBp and keeps a Buy rating on the shares. Despite the near-term COVID-19 uncertainties, the group's strong earnings recovery potential remains intact, the analyst tells investors in a research note. Pominkiewicz further cites the sustained basis for investment in the stock- namely, improving Summit Reheis and Mondo performance and cost savings.

EMNSF Elementis
$2.00 /

+ (+0.00%)

04/30/21 Morgan Stanley
Elementis price target raised to 148 GBp from 136 GBp at Morgan Stanley
04/27/21 JPMorgan
Elementis price target raised to 145 GBp from 130 GBp at JPMorgan
04/14/21 UBS
Elementis price target raised to 140 GBp from 130 GBp at UBS
02/25/21 Credit Suisse
Elementis price target raised to 150 GBp from 99 GBp at Credit Suisse

TODAY'S FREE FLY STORIES

Earnings
Starwood Property reports Q2 distributable EPS 51c, consensus 51c » 07:53
08/05/21
08/05
07:53
08/05/21
07:53
STWD

Starwood Property

$25.82 /

-0.21 (-0.81%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
STWD Starwood Property
$25.82 /

-0.21 (-0.81%)

08/04/21 JMP Securities
Starwood Property price target raised to $28 from $17 at JMP Securities
05/10/21 JPMorgan
Starwood Property price target raised to $26 from $25 at JPMorgan
04/26/21 JPMorgan
Starwood Property price target raised to $25 from $22 at JPMorgan
02/26/21 JPMorgan
Starwood Property price target raised to $22 from $21 at JPMorgan
STWD Starwood Property
$25.82 /

-0.21 (-0.81%)

Earnings
Salarius Pharmaceuticals reports Q2 EPS (7c), consensus (6c) » 07:53
08/05/21
08/05
07:53
08/05/21
07:53
SLRX

Salarius Pharmaceuticals

/

+

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SLRX Salarius Pharmaceuticals
/

+

  • 04
    Mar
Recommendations
Amdocs price target raised to $99 from $84 at Oppenheimer » 07:53
08/05/21
08/05
07:53
08/05/21
07:53
DOX

Amdocs

$75.03 /

-1.23 (-1.61%)

Oppenheimer analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DOX Amdocs
$75.03 /

-1.23 (-1.61%)

DOX Amdocs
$75.03 /

-1.23 (-1.61%)

04/01/21 JPMorgan
Amdocs should 'bounce-back' after short report, says JPMorgan
03/31/21 JPMorgan
Prior Amdocs short report turned out a 'great buying opportunity,' says JPMorgan
02/11/21 Oppenheimer
Amdocs assumed with an Outperform at Oppenheimer
02/03/21 Citi
Amdocs price target raised to $87 from $82 at Citi
DOX Amdocs
$75.03 /

-1.23 (-1.61%)

DOX Amdocs
$75.03 /

-1.23 (-1.61%)

Recommendations
Horizon Therapeutics price target raised to $132 from $118 at BMO Capital » 07:52
08/05/21
08/05
07:52
08/05/21
07:52
HZNP

Horizon Therapeutics

$107.54 /

+7.79 (+7.81%)

BMO Capital analyst Gary…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$107.54 /

+7.79 (+7.81%)

HZNP Horizon Therapeutics
$107.54 /

+7.79 (+7.81%)

06:28 Today Citi
Horizon Therapeutics price target raised to $121 from $117 at Citi
07/16/21 Piper Sandler
Horizon's Krystexxa poised for 'aggressive growth,' says Piper Sandler
06/21/21 Piper Sandler
Arrowhead price target raised to $109 from $99 at Piper Sandler
05/05/21 Cowen
Cowen would add to Horizon Therapeutics after 'nicely conservative' guidance
HZNP Horizon Therapeutics
$107.54 /

+7.79 (+7.81%)

  • 07
    Aug
Earnings
Quanta Services raises FY21 adjusted EPS view to $4.32-$4.68 from $4.12-$4.57 » 07:52
08/05/21
08/05
07:52
08/05/21
07:52
PWR

Quanta Services

$89.05 /

-2.17 (-2.38%)

Consensus $4.42. Raises…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

07/22/21 Citi
Citi opens 'positive catalyst watch' on Quanta Services into earnings
07/19/21 Cowen
Quanta Services initiated with an Outperform at Cowen
06/25/21 Citi
Citi sees infrastructure framework as 'tailwind' for infrastructure companies
06/08/21
Fly Intel: Top five analyst initiations
PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

Hot Stocks
Arbutus Biopharma expects cash to fund operations into Q3 of 2022 » 07:52
08/05/21
08/05
07:52
08/05/21
07:52
ABUS

Arbutus Biopharma

$2.76 /

+0.01 (+0.36%)

Arbutus had cash, cash…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

06/28/21 JMP Securities
Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
03/10/21 B. Riley Securities
Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
12/17/20 H.C. Wainwright
Arbutus Biopharma initiated with a Buy at H.C. Wainwright
09/15/20 Chardan
Arbutus HBV data 'could represent a turning point,' says Chardan
ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

Earnings
OGE Energy backs FY21 EPS in 'lower half' of $1.76-$1.86, consensus $2.18 » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
OGE

OGE Energy

$34.10 /

-0.265 (-0.77%)

The company reaffirms its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

06/11/21 BofA
OGE Energy upgraded to Buy from Neutral at BofA
05/25/21 Barclays
OGE Energy upgraded to Equal Weight from Underweight at Barclays
03/11/21 BofA
OGE Energy downgraded to Neutral from Buy at BofA
03/09/21 Wells Fargo
OGE Energy downgraded to Equal Weight at Wells Fargo
OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

Earnings
Provention Bio reports Q2 EPS (46c), consensus (52c) » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
PRVB

Provention Bio

$6.02 /

-0.195 (-3.14%)

Provention Bio expects…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PRVB Provention Bio
$6.02 /

-0.195 (-3.14%)

PRVB Provention Bio
$6.02 /

-0.195 (-3.14%)

07/09/21 Chardan
Provention Bio coverage transferred at Chardan
05/28/21 Chardan
Provention Bio price target lowered to $22.50 from $35 at Chardan
05/25/21 SVB Leerink
Provention Bio briefing documents a positive, says SVB Leerink
05/07/21 Cantor Fitzgerald
Provention Bio price target lowered to $19 from $25 at Cantor Fitzgerald
PRVB Provention Bio
$6.02 /

-0.195 (-3.14%)

  • 14
    Jan
PRVB Provention Bio
$6.02 /

-0.195 (-3.14%)

PRVB Provention Bio
$6.02 /

-0.195 (-3.14%)

Recommendations
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
ALLO

Allogene Therapeutics

$22.13 /

+0.23 (+1.05%)

Oppenheimer analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALLO Allogene Therapeutics
$22.13 /

+0.23 (+1.05%)

ALLO Allogene Therapeutics
$22.13 /

+0.23 (+1.05%)

05:29 Today Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
06/21/21 Jefferies
Allogene Therapeutics assumed with a Buy at Jefferies
05/20/21 Jefferies
Allogene update exceeds expectation 'on all fronts,' says Jefferies
05/20/21 Stifel
Allogene data 'better than they appear on the surface,' says Stifel
ALLO Allogene Therapeutics
$22.13 /

+0.23 (+1.05%)

ALLO Allogene Therapeutics
$22.13 /

+0.23 (+1.05%)

Earnings
Arbutus Biopharma reports Q2 EPS (23c), consensus (22c) » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
ABUS

Arbutus Biopharma

$2.76 /

+0.01 (+0.36%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

06/28/21 JMP Securities
Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
03/10/21 B. Riley Securities
Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
12/17/20 H.C. Wainwright
Arbutus Biopharma initiated with a Buy at H.C. Wainwright
09/15/20 Chardan
Arbutus HBV data 'could represent a turning point,' says Chardan
ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

ABUS Arbutus Biopharma
$2.76 /

+0.01 (+0.36%)

Earnings
Stratasys sees Q3 revenue growth 17% - 18% growth year-over-year » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
SSYS

Stratasys

$19.70 /

+0.07 (+0.36%)

Sees Q3 revenue of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

03/26/21 Lake Street
Desktop Metal initiated with a Sell at Lake Street
03/12/21 Lake Street
Stratasys initiated with a Buy at Lake Street
03/10/21 JPMorgan
Stratasys upgraded to Neutral after 50% pullback at JPMorgan
03/10/21 JPMorgan
Stratasys upgraded to Neutral from Underweight at JPMorgan
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

  • 03
    Mar
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

Upgrade
Morgan Stanley upgrades Virtus Investment to Overweight on better EPS growth » 07:51
08/05/21
08/05
07:51
08/05/21
07:51
VRTS

Virtus Investment

$285.16 /

+3.42 (+1.21%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VRTS Virtus Investment
$285.16 /

+3.42 (+1.21%)

VRTS Virtus Investment
$285.16 /

+3.42 (+1.21%)

05:16 Today Morgan Stanley
Virtus Investment upgraded to Overweight from Equal Weight at Morgan Stanley
02/03/21 Barclays
Virtus Investment price target raised to $315 from $280 at Barclays
01/25/21 Barclays
Virtus Investment price target raised to $280 from $270 at Barclays
10/26/20 Barclays
Virtus Investment price target raised to $215 from $180 at Barclays
VRTS Virtus Investment
$285.16 /

+3.42 (+1.21%)

Earnings
InflaRx reports Q2 EPS (EUR0.33) vs. (EUR0.38) last year » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
IFRX

InflaRx

$2.49 /

-0.03 (-1.19%)

"I am very pleased…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IFRX InflaRx
$2.49 /

-0.03 (-1.19%)

IFRX InflaRx
$2.49 /

-0.03 (-1.19%)

03/26/21 H.C. Wainwright
InflaRx price target lowered to $10 from $12 at H.C. Wainwright
03/11/21 Guggenheim
InflaRx upgraded to Buy from Neutral at Guggenheim
01/12/21 H.C. Wainwright
InflaRx price target raised to $12 from $11 at H.C. Wainwright
11/06/20 SVB Leerink
InflaRx upgraded to Outperform from Market Perform at SVB Leerink
IFRX InflaRx
$2.49 /

-0.03 (-1.19%)

  • 25
    Feb
Earnings
OGE Energy reports Q2 EPS 56c, consensus 53c » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
OGE

OGE Energy

$34.10 /

-0.265 (-0.77%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

06/11/21 BofA
OGE Energy upgraded to Buy from Neutral at BofA
05/25/21 Barclays
OGE Energy upgraded to Equal Weight from Underweight at Barclays
03/11/21 BofA
OGE Energy downgraded to Neutral from Buy at BofA
03/09/21 Wells Fargo
OGE Energy downgraded to Equal Weight at Wells Fargo
OGE OGE Energy
$34.10 /

-0.265 (-0.77%)

Earnings
Quanta Services reports Q2 adjusted EPS $1.06, consensus $1.04 » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
PWR

Quanta Services

$89.05 /

-2.17 (-2.38%)

Reports Q2 revenue $3B,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

07/22/21 Citi
Citi opens 'positive catalyst watch' on Quanta Services into earnings
07/19/21 Cowen
Quanta Services initiated with an Outperform at Cowen
06/25/21 Citi
Citi sees infrastructure framework as 'tailwind' for infrastructure companies
06/08/21
Fly Intel: Top five analyst initiations
PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

PWR Quanta Services
$89.05 /

-2.17 (-2.38%)

Recommendations
Sealed Air price target raised to $62 from $52 at BMO Capital » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
SEE

Sealed Air

$57.99 /

-0.54 (-0.92%)

BMO Capital analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SEE Sealed Air
$57.99 /

-0.54 (-0.92%)

SEE Sealed Air
$57.99 /

-0.54 (-0.92%)

08/03/21 BofA
Sealed Air price target raised to $72 from $67 at BofA
05/06/21 BMO Capital
Sealed Air price target raised to $52 from $42 at BMO Capital
05/05/21
Fly Intel: Top five analyst upgrades
05/05/21 Baird
Sealed Air price target raised to $72 from $56 at Baird
SEE Sealed Air
$57.99 /

-0.54 (-0.92%)

SEE Sealed Air
$57.99 /

-0.54 (-0.92%)

General news
Treasury Market Outlook: Treasuries and EGBs have recouped earlier losses » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
$ECON

Economic Data

/

+

Treasury Market Outlook:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

Earnings
Strongbridge maintains FY21 revenue guidance $34M-$36M, consensus $36.28M » 07:50
08/05/21
08/05
07:50
08/05/21
07:50
SBBP

Strongbridge Biopharma

$2.30 /

-0.07 (-2.95%)

The Company maintains…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

05/25/21 Craig-Hallum
Strongbridge downgraded to Hold at Craig-Hallum on Xeris acquisition
05/25/21 Craig-Hallum
Strongbridge Biopharma downgraded to Hold from Buy at Craig-Hallum
05/25/21 Mizuho
Xeris Pharmaceuticals price target lowered to $9 from $14 at Mizuho
05/25/21 JMP Securities
Strongbridge downgraded to Market Perform from Outperform at JMP Securities
SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

  • 17
    Sep
SBBP Strongbridge Biopharma
$2.30 /

-0.07 (-2.95%)

Hot Stocks
Dyne Therapeutics expects cash to fund requirements into 2H24 » 07:49
08/05/21
08/05
07:49
08/05/21
07:49
DYN

Dyne Therapeutics

$18.32 /

+0.76 (+4.33%)

Cash, cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

Earnings
Dyne Therapeutics reports Q2 EPS (58c), consensus (54c) » 07:49
08/05/21
08/05
07:49
08/05/21
07:49
DYN

Dyne Therapeutics

$18.32 /

+0.76 (+4.33%)

"We were pleased to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$18.32 /

+0.76 (+4.33%)

Earnings
Stratasys reports Q2 EPS (2c), consensus (7c) » 07:49
08/05/21
08/05
07:49
08/05/21
07:49
SSYS

Stratasys

$19.70 /

+0.07 (+0.36%)

Reports Q2 revenue $147M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

03/26/21 Lake Street
Desktop Metal initiated with a Sell at Lake Street
03/12/21 Lake Street
Stratasys initiated with a Buy at Lake Street
03/10/21 JPMorgan
Stratasys upgraded to Neutral after 50% pullback at JPMorgan
03/10/21 JPMorgan
Stratasys upgraded to Neutral from Underweight at JPMorgan
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

  • 03
    Mar
SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

SSYS Stratasys
$19.70 /

+0.07 (+0.36%)

Earnings
Kimbell Royalty Partners reports Q2 EPS 4c, consensus 8c » 07:49
08/05/21
08/05
07:49
08/05/21
07:49
KRP

Kimbell Royalty Partners

$11.08 /

-0.32 (-2.81%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KRP Kimbell Royalty Partners
$11.08 /

-0.32 (-2.81%)

KRP Kimbell Royalty Partners
$11.08 /

-0.32 (-2.81%)

03/18/21 Wells Fargo
Kimbell Royalty Partners downgraded to Equal Weight at Wells Fargo
03/18/21 Wells Fargo
Kimbell Royalty downgraded to Equal Weight from Overweight at Wells Fargo
KRP Kimbell Royalty Partners
$11.08 /

-0.32 (-2.81%)

Recommendations
Tandem Diabetes price target raised to $140 from $135 at Oppenheimer » 07:49
08/05/21
08/05
07:49
08/05/21
07:49
TNDM

TNDM

/

+

Oppenheimer analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TNDM TNDM
/

+

TNDM TNDM
/

+

07/21/21 Cowen
Tandem Diabetes transferred with Outperform rating at Cowen
05/27/21 Piper Sandler
Medtronic price target raised to $140 from $130 at Piper Sandler
05/25/21 Barclays
Barclays starts Medical Devices sector with Positive industry view
05/24/21 Barclays
Tandem Diabetes initiated with an Underweight at Barclays
TNDM TNDM
/

+

Earnings
Sempra Energy backs FY21 adjusted EPS view $7.75-$8.35, consensus $8.10 » 07:48
08/05/21
08/05
07:48
08/05/21
07:48
SRE

Sempra Energy

$130.88 /

-1.105 (-0.84%)

Backs FY21 adjusted EPS…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SRE Sempra Energy
$130.88 /

-1.105 (-0.84%)

SRE Sempra Energy
$130.88 /

-1.105 (-0.84%)

07/07/21 Goldman Sachs
Sempra Energy downgraded to Buy from Conviction Buy at Goldman Sachs
06/30/21
Fly Intel: Top five analyst downgrades
06/30/21 BofA
Sempra Energy downgraded to Neutral from Buy at BofA
06/28/21 Mizuho
Sempra Energy price target raised to $154 from $148 at Mizuho
SRE Sempra Energy
$130.88 /

-1.105 (-0.84%)

SRE Sempra Energy
$130.88 /

-1.105 (-0.84%)

SRE Sempra Energy
$130.88 /

-1.105 (-0.84%)

Earnings
Parker-Hannifin sees 2022 adjusted EPS $16.20-$17.00, consensus $17.08 » 07:48
08/05/21
08/05
07:48
08/05/21
07:48
PH

Parker-Hannifin

$303.40 /

-5.96 (-1.93%)

For the fiscal year…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

08/03/21 Berenberg
Meggitt downgraded to Hold from Buy at Berenberg
08/02/21 Baird
Baird says Parker-Hannifin paid 'robust' price for Meggitt, has good M&A record
06/23/21
Fly Intel: Top five analyst upgrades
06/23/21 KeyBanc
KeyBanc upgrades Parker-Hannifin to Overweight on 'multiyear upcycle'
PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

PH Parker-Hannifin
$303.40 /

-5.96 (-1.93%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.